Der­mi­ra sweeps PhI­II pso­ri­a­sis stud­ies for Cimzia as ri­vals threat­en an­oth­er en­try

Der­mi­ra has wrapped the third and fi­nal pso­ri­a­sis study of Cimzia, which the biotech says cleared the fi­nal hur­dles in the lead up to an FDA fil­ing lat­er this year.

This lat­est study — trig­gered by a de­vel­op­ment deal Der­mi­ra struck with UCB in 2014 for US and EU rights to the rheuma­toid arthri­tis drug — gath­ered up fresh ev­i­dence of Cimzia’s ef­fec­tive­ness in pso­ri­a­sis, in­clud­ing a beat over En­brel with a 400 mg dose at week 12 and non­in­fe­ri­or­i­ty over En­brel at 200 mg. The pri­ma­ry end­point was the week 12 PASI 75 score on clear­ance, and the an­ti-TNF ther­a­py came in at 66.7% for pa­tients re­ceiv­ing the 400 mg dose every two weeks and 61.3.% for pa­tients re­ceiv­ing the CIMZIA 200 mg dose every two weeks, com­pared to 5.0% for pa­tients re­ceiv­ing place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER